Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Concord Healthcare Group Co's revenue for the
six
months ended in Jun. 2026 was HK$311.9 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was HK$598.1 Mil.
Concord Healthcare Group Co's Revenue per Share for the
six
months ended in Jun. 2026 was HK$0.39.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was HK$0.76.
Warning Sign:
Concord Healthcare Group Co Ltd revenue per share has been in decline over the past 3 years.
During the past 6 years, Concord Healthcare Group Co's highest 3-Year average Revenue per Share Growth Rate was 44.00% per year. The lowest was -10.40% per year. And the median was -2.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Concord Healthcare Group Co Revenue Related Terms
Concord Healthcare Group Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Concord Healthcare Group Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Concord Healthcare Group Co Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Concord Healthcare Group Co's Revenue distribution charts can be found below:
* The bar in red indicates where Concord Healthcare Group Co's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$598.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Concord Healthcare Group Co (HKSE:02453) has a Revenue of HK$598.1 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Concord Healthcare Group Co and its competitors.
Is Concord Healthcare Group Co's Revenue too high?
Concord Healthcare Group Co's current Revenue is HK$598.1 Mil. Overall, Concord Healthcare Group Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Concord Healthcare Group Co's Revenue compare to HCA and THC?
Concord Healthcare Group Co's Revenue of HK$598.1 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Concord Healthcare Group Co and its competitors. Concord Healthcare Group Co's current Revenue is HK$598.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Healthcare Group Co stock overvalued right now?
Based on GuruFocus' analysis, Concord Healthcare Group Co (HKSE:02453) is currently considered Possible Value Trap. The stock's GF Value™ is HK$8.63, compared to a current price of HK$0.73 — trading 91.5% below its estimated fair value. The current Revenue is HK$598.1 Mil. Concord Healthcare Group Co's overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Concord Healthcare Group Co (HKSE:02453), the current Revenue is HK$598.1 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Concord Healthcare Group Co (HKSE:02453) Overvalued in 2026?
Based on GuruFocus' analysis, Concord Healthcare Group Co stock appears to be undervalued.
The current stock price of HK$0.73 is trading 91.5% below its estimated GF Value™ of HK$8.63.
GuruFocus considers Concord Healthcare Group Co to be Possible Value Trap.
Key valuation signals for HKSE:02453:
Revenue: HK$598.1 Mil
GF Value™: HK$8.63 vs. price of HK$0.73 (91.5% below fair value)
No single metric tells the full story. See the HKSE:02453 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Concord Healthcare Group Co Ltd is a healthcare service provider in China that specializes in oncology. The Group owns and operates four offline self-operated medical institutions and one medical institution under construction, dedicated to providing comprehensive and specialized medical services to cancer patients. It also provides medical equipment, software, and related services to third-party medical institutions. The company's revenue is generated from its hospital business and its medical equipment, software, and related services segment. Substantially all of the company's revenue is generated from the PRC.
41GF Score
Get the complete analysis for HKSE:02453
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02453 has been successfully added to your 
